Read our latest updates from research breakthroughs to government actions to fundraising heroes. You can also read personal stories from women and their families directly affected by ovarian cancer.
Target Ovarian Cancer has found that as many as one in every five women (20 per cent) in England is too ill to treat by the time they receive their ovarian cancer diagnosis, according to data released this week.
Target Ovarian Cancer's new project represents a new frontier in ovarian cancer research.
This time last year, we launched our ‘It’s time to TAKE OVAR’ campaign. The campaign aims to transform the futures of more than 25,000 women in the UK who are living with ovarian cancer – and thousands more who are yet to be diagnosed.
Today, the National Institute for Health and Care Excellence (NICE) has published some draft guidance about ovarian cancer drug olaparib (Lynparza®).
Rebecca Rennison, Target Ovarian Cancer’s Director of Public Affairs and Services, has been working to make sure NHS England’s new approach to speedier diagnosis works for women with ovarian cancer.
Sign up to receive emails from Target Ovarian Cancer, including our monthly newsletter, and be the first to hear about campaigns, upcoming events and fundraising inspiration.
Sign up
